Multiple myeloma has a name that sounds as though it belongs in a difficult spelling bee, and the disease itself can be just as confusing. Is it bone cancer? Does every patient need chemotherapy immediately? Can sugar make it grow faster? Does remission mean the cancer is gone forever?
Unfortunately, myths tend to travel faster than careful medical explanations. They also arrive with more confidence, fewer footnotes, and occasionally a suspicious bottle of “miracle” supplements. Reliable facts are less dramatic, but they are far more useful when someone is facing a diagnosis, supporting a loved one, or trying to understand an abnormal laboratory result.
Multiple myeloma is a cancer of plasma cells, which are antibody-producing white blood cells located mainly in bone marrow. Cancerous plasma cells can crowd out healthy blood-forming cells, produce abnormal proteins, weaken bones, impair kidney function, raise calcium levels, and interfere with the immune system. Its symptoms, progression, and response to treatment vary considerably from one person to another.
Myth 1: Multiple Myeloma Is the Same as Bone Cancer
Fact: It is a blood cancer that can seriously damage bones
Multiple myeloma begins in plasma cells, not in the structural cells that form bone. For that reason, it is classified as a hematologic, or blood, cancer rather than a primary bone cancer.
The confusion is understandable because myeloma frequently affects the skeleton. Abnormal plasma cells can stimulate bone breakdown and interfere with normal bone rebuilding. This may create weakened areas called lytic lesions, increase the risk of fractures, or cause persistent pain in the back, ribs, hips, chest, or other areas.
In other words, multiple myeloma is not born in the bone itself, but it can behave like a terrible upstairs neighbor once it moves into the bone marrow. Bone-strengthening medications, pain management, radiation, and sometimes surgery may be used alongside treatment directed at the myeloma cells.
Myth 2: Multiple Myeloma Is Contagious
Fact: You cannot catch it from another person
Multiple myeloma is not caused by a contagious virus or bacterium, and it cannot spread through coughing, touching, sharing food, sexual contact, or living with someone who has the disease.
The cancer develops when a plasma cell acquires biological changes that allow it to multiply abnormally. Researchers do not fully understand why this process occurs in a particular person. Known risk factors can affect probability, but they do not make the disease transmissible.
Myth 3: Multiple Myeloma Is Directly Inherited
Fact: Family history may influence risk, but most patients have no affected relative
Multiple myeloma does not usually follow a simple inherited pattern in which a parent passes a single disease-causing gene to a child. Having a parent or sibling with myeloma may increase a person’s risk, but family history accounts for only a small proportion of cases. Most people diagnosed with the disease do not have a close relative who also has it.
Risk increases with age, and the disease is diagnosed more often in men than women. In the United States, multiple myeloma is also more than twice as common in Black people as in White people, although the reasons for this disparity are not completely understood. A risk factor is not a prediction: many people with one or more risk factors never develop myeloma.
Myth 4: The Symptoms Are Always Obvious
Fact: Early multiple myeloma may cause vague symptoms or no symptoms at all
Some patients are diagnosed after routine blood work reveals anemia, abnormal protein levels, kidney changes, or elevated calcium. Others seek care for fatigue, repeated infections, unexplained weight loss, bone pain, weakness, easy bruising, or a fracture caused by relatively minor stress.
These warning signs are not unique to myeloma. Fatigue could come from poor sleep, anemia, medication, thyroid disease, stress, or approximately half of modern life. Back pain is also extremely common and is usually caused by something other than cancer.
However, persistent or worsening bone pain deserves medical attention, particularly when it appears alongside unusual fatigue, recurrent infections, shortness of breath, kidney problems, confusion, excessive thirst, frequent urination, unexplained fractures, or abnormal laboratory results.
Myth 5: An Abnormal Protein Test Automatically Means Active Multiple Myeloma
Fact: Several plasma-cell conditions can produce abnormal proteins
A monoclonal protein, often called an M protein or M spike, may be found during blood or urine testing. Its presence can be associated with multiple myeloma, but it can also occur in monoclonal gammopathy of undetermined significance, commonly shortened to MGUS, or in smoldering multiple myeloma.
MGUS is a precursor condition rather than active myeloma. It generally does not cause organ damage and is usually monitored instead of treated. Smoldering multiple myeloma involves a greater amount of abnormal plasma-cell activity but may still lack the organ damage or other myeloma-defining features seen in active disease.
Risk matters. Many people with MGUS and some people with smoldering myeloma continue with careful monitoring. Treatment may be considered for selected high-risk cases. In November 2025, the FDA approved daratumumab and hyaluronidase-fihj for adults with high-risk smoldering multiple myeloma, illustrating how management is evolving beyond the old assumption that every asymptomatic patient must simply wait.
Myth 6: One Blood Test Can Confirm the Diagnosis
Fact: Diagnosis usually requires several types of evidence
No single laboratory value tells the complete story. A multiple myeloma evaluation may include a complete blood count, metabolic panel, serum protein electrophoresis, immunofixation, free light-chain testing, urine studies, bone marrow aspiration or biopsy, genetic testing of myeloma cells, and imaging such as low-dose CT, MRI, or PET/CT.
Doctors assess the amount and biological characteristics of abnormal plasma cells while looking for myeloma-defining events. These can include anemia, kidney impairment, high blood calcium, bone lesions, or specific biomarker thresholds associated with a high risk of organ damage.
The process can feel like being assigned an entire season of medical detective television at once. Each test, however, answers a different question: Is myeloma present? How active is it? Has it affected organs? What is its risk profile? Which treatment is most appropriate?
Myth 7: Every Patient Must Start Treatment Immediately
Fact: Treatment timing depends on disease activity and risk
Active multiple myeloma that is causing organ damage or meets recognized myeloma-defining criteria generally requires treatment. Delaying therapy in that situation may allow worsening kidney injury, fractures, anemia, infection, or other complications.
That does not mean every plasma-cell abnormality demands immediate medication. MGUS is usually monitored. Some cases of smoldering myeloma are monitored closely, while high-risk smoldering disease may now be treated in selected circumstances. Even active myeloma treatment is tailored according to symptoms, kidney function, genetic risk, overall fitness, other medical conditions, and patient preferences.
“Watchful waiting” is not the same as ignoring the disease. It involves scheduled examinations, laboratory testing, and sometimes repeat imaging so that meaningful progression can be identified promptly.
Myth 8: Treatment Is Just Traditional Chemotherapy
Fact: Modern care may combine several treatment classes
Traditional chemotherapy can still have a role, but contemporary multiple myeloma treatment is much broader. Depending on the situation, a regimen may contain a proteasome inhibitor, an immunomodulatory drug, a corticosteroid, a monoclonal antibody, targeted therapy, or another immune-based treatment.
Additional options can include autologous stem cell transplantation, maintenance therapy, radiation for a painful or threatening bone lesion, CAR T-cell therapy, and bispecific antibodies that help immune cells recognize and attack myeloma cells. The FDA has continued approving new combinations and therapies for newly diagnosed, relapsed, refractory, and high-risk disease.
The best plan is not automatically the newest or most aggressive one. It is the plan that offers an appropriate balance of disease control, side effects, organ protection, convenience, long-term strategy, and the patient’s priorities.
Myth 9: A Stem Cell Transplant Is Major Surgery
Fact: An autologous transplant is an intensive medical treatment, not an operation
For an autologous stem cell transplant, blood-forming stem cells are collected from the patient and stored. The patient then receives high-dose chemotherapy to reduce myeloma cells, after which the stored stem cells are returned through an intravenous line to help restore blood production.
There is no surgeon removing the myeloma with a scalpel. Nevertheless, transplantation is a major treatment with real risks, including low blood counts, fatigue, infection, mouth sores, and the need for close monitoring.
Age alone does not determine eligibility. Doctors consider fitness, heart and lung function, kidney health, other conditions, disease characteristics, and personal goals. Some people benefit from transplantation, while others receive effective non-transplant regimens.
Myth 10: Remission Means the Disease Is Permanently Cured
Fact: Remission is excellent news, but continued monitoring remains essential
A remission means treatment has greatly reduced detectable signs of myeloma and improved disease-related problems. Responses can range from partial to very deep, and doctors may use blood tests, urine tests, imaging, bone marrow findings, and measurable residual disease assessments to evaluate them.
Multiple myeloma is still generally regarded as treatable but not reliably curable. Myeloma cells may eventually begin growing again, even after an excellent response. That is why maintenance therapy and long-term follow-up are often important.
Relapse does not mean the patient “failed” treatment or has run out of options. It means the disease has changed or re-emerged and the treatment strategy must be reconsidered. The growing number of available drug classes and immune therapies allows many patients to receive several effective lines of treatment over time. Outcomes have improved substantially as these options have expanded.
Myth 11: Sugar, Supplements, or a Special Diet Can Cure Myeloma
Fact: Nutrition supports health, but it does not replace cancer treatment
Cancer cells use glucose, but so do healthy cells. Research has not shown that eliminating sugar makes an existing cancer disappear. Similarly, no vitamin, herb, detox program, alkaline diet, juice protocol, or supplement combination has been proven to cure multiple myeloma.
Some supplements may also interfere with medications, affect bleeding risk, or strain the kidneys or liver. “Natural” is a marketing category, not a guarantee of safety. Poison ivy is natural, too, and nobody is adding it to a wellness smoothie.
Good nutrition can still matter enormously. Adequate calories, protein, fluids, and nutrients may help patients maintain strength, manage weight changes, and tolerate treatment. Dietary needs can change with kidney impairment, high calcium, nausea, mouth sores, infection risk, diabetes, or medication side effects, making individualized advice from the care team or an oncology dietitian especially valuable.
Myth 12: People With Myeloma Should Avoid All Exercise
Fact: Appropriate movement can help, but bone safety comes first
Physical activity may improve strength, mobility, sleep, mood, and cancer-related fatigue. Yet multiple myeloma can weaken bones, so generic exercise advice may be unsafe for someone with lytic lesions, spinal compression, severe anemia, neuropathy, balance problems, or a high fracture risk.
The safest plan may involve walking, supervised resistance work, physical therapy, balance exercises, or modified weight-bearing activity. High-impact movements, heavy lifting, twisting, or exercises that load vulnerable areas may need to be avoided. Patients should ask their treatment team whether imaging or a physical-therapy assessment is needed before changing their routine.
Myth 13: Palliative Care Means Giving Up
Fact: Supportive care can be used at any stage
Palliative or supportive care focuses on comfort, function, and quality of life. It may address pain, nausea, fatigue, sleep problems, anemia, infections, neuropathy, emotional distress, or the side effects of treatment.
It can be provided at the same time as active anticancer therapy. It is not identical to hospice care, and it does not mean treatment is stopping. In myeloma, supportive care may include bone-strengthening medication, infection prevention, transfusions, pain treatment, rehabilitation, mental-health support, and help managing practical problems.
Myth 14: Clinical Trials Are Only for People With No Options Left
Fact: Trials may be relevant at several points in care
Some clinical trials study treatments for heavily pretreated myeloma, but others examine newly diagnosed disease, maintenance therapy, earlier use of immune treatments, supportive care, or high-risk precursor conditions.
Participation is voluntary, and a trial is not automatically better than established care. Patients should ask about the purpose of the study, alternatives, potential risks, added appointments, costs, travel, randomization, and how participation may affect later treatment choices. Discussing a trial early simply keeps the door open; it does not require walking through it.
Experiences Related to Multiple Myeloma: What the Journey Can Feel Like
The following examples are illustrative composites based on commonly reported patient and caregiver experiences. They are not quotations from identifiable individuals and should not be interpreted as predictions of any one person’s course.
The diagnosis may begin with something surprisingly ordinary
For some people, the journey starts not with a dramatic emergency but with ordinary complaints that refuse to leave. A person may notice persistent back pain and blame an old mattress, yard work, or the regrettable confidence with which they once lifted a heavy box. Another may feel unusually exhausted but assume that age, work, or poor sleep is responsible.
Then routine blood tests show anemia, elevated creatinine, high calcium, or an unusual protein level. Additional tests follow. New vocabulary arrives at high speed: M protein, free light chains, plasma-cell percentage, FISH testing, lytic lesions, staging, transplant eligibility. Many patients describe this period as emotionally disorienting because they are learning a new language while also trying to understand a serious diagnosis.
The waiting between tests can be difficult. A scan may be scheduled several days away, followed by a bone marrow biopsy and another appointment to discuss results. Friends may offer enthusiastic reassurance before the medical facts are known. Others may search online and encounter statistics stripped of context. Both reactions can be stressful. A written list of questions and a second set of ears at appointments often make the information easier to absorb.
Treatment can become a calendar-management project
Once therapy begins, daily life may revolve around medication schedules, infusion visits, laboratory checks, pharmacy deliveries, insurance calls, infection precautions, and side-effect management. Some treatments are given at a clinic, while others are taken at home. A regimen that sounds simple on paper can involve antiviral medication, blood-clot prevention, bone treatment, nausea medication, and several rules about when to call the care team.
Corticosteroids such as dexamethasone create a particularly memorable experience for some patients. A person may feel unusually energetic on treatment day, reorganize a closet at midnight, and then experience irritability, insomnia, increased appetite, or a pronounced energy crash. These effects are medical, not moral. Adjusting the dose or schedule may sometimes help, but changes should be made only with the prescribing team.
Fatigue may also be inconsistent. A patient can feel capable in the morning and depleted by afternoon, or function well one week and struggle the next. Learning to plan around energy rather than forcing a previous routine can reduce frustration. Short walks, rest periods, help with meals, and permission to decline nonessential commitments may be more useful than heroic attempts to “push through.”
Laboratory numbers can become emotionally powerful
Patients often become skilled readers of their own test results. Hemoglobin, creatinine, calcium, M protein, immunoglobulins, and free light chains can begin to feel like characters in an ongoing drama. A favorable result may bring relief. A small change may trigger anxiety long before the doctor has interpreted whether it is medically meaningful.
This phenomenon is sometimes called scan anxiety or test anxiety, although myeloma patients may experience it with monthly blood work as much as with imaging. It can help to ask which changes are expected, which trends matter most, and what threshold would lead to a treatment adjustment. A single value may be less important than its pattern over time.
Remission can bring relief and uncertainty at the same time
Reaching remission is often a major emotional milestone. Pain may improve, blood counts may recover, and normal routines may gradually return. Yet follow-up appointments can serve as repeated reminders that the disease has not been erased from the calendar.
Some patients find that other people expect life to return instantly to “normal.” The patient may still be dealing with neuropathy, weakness, infection concerns, medication fatigue, financial pressure, or fear of relapse. Recovery is rarely a switch that flips from sick to perfectly fine. It is more often a gradual renegotiation of work, exercise, family roles, priorities, and expectations.
Caregivers travel a parallel road
Caregivers may coordinate transportation, medications, meals, insurance documents, household duties, and communication with relatives. They may try to remain cheerful while privately experiencing anxiety, exhaustion, or depression. Research has highlighted a substantial emotional burden among caregivers of people with multiple myeloma, sometimes even when the patient appears to be coping relatively well.
Practical support is often more useful than vague offers. “I can drive you to Tuesday’s appointment” is easier to accept than “Call me if you need anything.” Caregivers also need rest, medical care, honest conversations, and time away from cancer-related tasks without feeling guilty.
Experience teaches patients which questions matter
Over time, many people learn to ask more precise questions: What is the goal of this treatment? How will we know whether it is working? Which side effects require an urgent call? How might this choice affect future options? Should a myeloma specialist review the plan? Is a clinical trial appropriate? What can be done to protect bones, kidneys, and immune function?
Perhaps the most useful lesson is that there is no single “typical” myeloma journey. Two people with the same diagnosis may have different genetic risk features, symptoms, medical conditions, responses, preferences, and treatment histories. Comparisons can provide community, but they should not become fortune-telling.
Conclusion: Replace Fearful Myths With Useful Questions
Multiple myeloma is serious, complicated, and still generally considered incurable, but those facts do not tell the entire story. It is also increasingly treatable, supported by a rapidly expanding range of medications, immune therapies, transplant strategies, clinical trials, and supportive-care options.
The most damaging myths are usually the absolute ones: every patient must be treated immediately, one diet cures everyone, a relapse means there is no hope, or age alone decides what treatment is possible. In reality, multiple myeloma care is highly individualized.
Accurate information gives patients and families something more useful than false certainty: better questions. Understanding the difference between MGUS, smoldering myeloma, and active disease; knowing why multiple tests are needed; recognizing important symptoms; and discussing treatment goals openly can make an intimidating diagnosis more manageable.
Editorial source note: The medical information in this article was synthesized from current patient and professional resources published by the National Cancer Institute, American Cancer Society, National Library of Medicine, American Society of Hematology, U.S. Food and Drug Administration, SEER Program, Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, Dana-Farber Cancer Institute, Multiple Myeloma Research Foundation, International Myeloma Foundation, and The Leukemia & Lymphoma Society.
